AAD 2026Abstract 73228
Durability of Response With Icotrokinra, a Targeted Oral Peptide, in Adults With Moderate-to-Severe Plaque Psoriasis
One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials
Gold LS, Armstrong AW, Soung J, Vender RB, Cantero ÁG, Hoffmann M, Reyes-Servin O, Edem BE, Cresswell K, Yang YW, Bissonnette R
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Psoriasis
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.698 · Not in PubMed: details from Crossref